Pomerantz Law Firm Files Class Action Against Biohaven Ltd. Over Securities Violations
On July 22, 2025, Pomerantz LLP, a well-regarded law firm, announced the filing of a class action lawsuit against Biohaven Ltd. (NYSE: BHVN) and several of its top officials. This legal action has been brought in the United States District Court for the District of Connecticut, under the docket number 25-cv-01120. The lawsuit primarily targets individuals and entities who purchased or acquired Biohaven securities between March 24, 2023, and May 14, 2025, during what is termed the 'Class Period'.
The suit aims to seek damages caused by alleged violations of federal securities laws by the defendants, specifically targeting Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 articulated therein. The firm has urged investors who fit this description to consider stepping forward as lead plaintiffs in the lawsuit before the deadline of September 12, 2025.
Biohaven Ltd. is a biopharmaceutical entity that focuses on discovering, developing, and commercializing treatments primarily in the fields of immunology, neuroscience, and oncology. Among their notable product candidates is Troriluzole, targeted for the treatment of spinocerebellar ataxia (SCA), and BHV-7000, being developed for bipolar disorder.
However, the litigation stems from serious concerns surrounding these products, particularly following a Phase 3 trial intended to evaluate Troriluzole's efficacy for treating SCA, which did not meet its primary endpoint. Despite this setback, company executives allegedly continued to promote Troriluzole as a viable treatment option, leading to accusations that they misrepresented its regulatory prospects and efficacy.
In a significant development in May 2023, Biohaven applied for a New Drug Application (NDA) for Troriluzole with the U.S. FDA. The subsequent months have seen various announcements. Most notably, in July 2023, it came to light that the FDA rejected the NDA due to the earlier trial's failure to meet its key objectives, triggering a sharp decline in Biohaven’s stock price, dropping by over 22% in a single day.
In December 2024, Biohaven indicated it had resubmitted the NDA following additional efficacy data that it deemed positive. However, troubling reports continued to surface regarding the company’s clinical prospects. In both March and April 2025, further announcements revealed limitations in the efficacy data for BHV-7000 and a withdrawal from the European Medicines Agency (EMA) concerning the Troriluzole drug application, leading to yet another substantial drop in stock price.
As the litigation progresses, investors await more clarity regarding the ongoing regulatory processes and any implications for Biohaven’s financial health and future viability.
Pomerantz LLP, with a distinguished legacy of over 85 years, has a robust track record in handling corporate, securities, and antitrust class actions. Founded by Abraham L. Pomerantz, who was instrumental in shaping the field of securities litigation, the firm has successfully recovered billions on behalf of individuals affected by corporate fraud.
For investors impacted by the incidents surrounding Biohaven Ltd., Pomerantz offers a channel for justice and potential recovery of losses. As always, those interested in pursuing this matter or seeking more information can contact Danielle Peyton at Pomerantz for further assistance. You may reach her at [email protected] or call 646-581-9980, extension 7980, for support.
Given the current climate surrounding securities law and corporate accountability, this action against Biohaven is emblematic of a growing desire among investors for greater transparency and leadership accountability in the medical and pharmaceutical fields.
The suit aims to seek damages caused by alleged violations of federal securities laws by the defendants, specifically targeting Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 articulated therein. The firm has urged investors who fit this description to consider stepping forward as lead plaintiffs in the lawsuit before the deadline of September 12, 2025.
Biohaven Ltd. is a biopharmaceutical entity that focuses on discovering, developing, and commercializing treatments primarily in the fields of immunology, neuroscience, and oncology. Among their notable product candidates is Troriluzole, targeted for the treatment of spinocerebellar ataxia (SCA), and BHV-7000, being developed for bipolar disorder.
However, the litigation stems from serious concerns surrounding these products, particularly following a Phase 3 trial intended to evaluate Troriluzole's efficacy for treating SCA, which did not meet its primary endpoint. Despite this setback, company executives allegedly continued to promote Troriluzole as a viable treatment option, leading to accusations that they misrepresented its regulatory prospects and efficacy.
In a significant development in May 2023, Biohaven applied for a New Drug Application (NDA) for Troriluzole with the U.S. FDA. The subsequent months have seen various announcements. Most notably, in July 2023, it came to light that the FDA rejected the NDA due to the earlier trial's failure to meet its key objectives, triggering a sharp decline in Biohaven’s stock price, dropping by over 22% in a single day.
In December 2024, Biohaven indicated it had resubmitted the NDA following additional efficacy data that it deemed positive. However, troubling reports continued to surface regarding the company’s clinical prospects. In both March and April 2025, further announcements revealed limitations in the efficacy data for BHV-7000 and a withdrawal from the European Medicines Agency (EMA) concerning the Troriluzole drug application, leading to yet another substantial drop in stock price.
As the litigation progresses, investors await more clarity regarding the ongoing regulatory processes and any implications for Biohaven’s financial health and future viability.
Pomerantz LLP, with a distinguished legacy of over 85 years, has a robust track record in handling corporate, securities, and antitrust class actions. Founded by Abraham L. Pomerantz, who was instrumental in shaping the field of securities litigation, the firm has successfully recovered billions on behalf of individuals affected by corporate fraud.
For investors impacted by the incidents surrounding Biohaven Ltd., Pomerantz offers a channel for justice and potential recovery of losses. As always, those interested in pursuing this matter or seeking more information can contact Danielle Peyton at Pomerantz for further assistance. You may reach her at [email protected] or call 646-581-9980, extension 7980, for support.
Given the current climate surrounding securities law and corporate accountability, this action against Biohaven is emblematic of a growing desire among investors for greater transparency and leadership accountability in the medical and pharmaceutical fields.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.